{"organizations": [], "uuid": "046499493be242eecc4a05b881568e1951adc8bc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vanda-pharmaceuticals-gets-paragra/brief-vanda-pharmaceuticals-gets-paragraph-iv-certification-notice-for-generic-version-of-hetlioz-capsule-idUSFWN1R80HD", "country": "US", "domain_rank": 408, "title": "BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-03-26T19:56:00.000+03:00", "replies_count": 0, "uuid": "046499493be242eecc4a05b881568e1951adc8bc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vanda-pharmaceuticals-gets-paragra/brief-vanda-pharmaceuticals-gets-paragraph-iv-certification-notice-for-generic-version-of-hetlioz-capsule-idUSFWN1R80HD", "ord_in_thread": 0, "title": "BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule", "locations": [], "entities": {"persons": [{"name": "vanda", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "vanda pharmaceuticals", "sentiment": "negative"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE\n* VANDA SAYS IN LETTER, TEVA ALLEGES SOME PATENTS WILL NOT BE INFRINGED BY ITS USE OR SALE OF 20MG HETLIOZ - SEC FILING Source text ( bit.ly/2pFMoh0 ) Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://bit.ly/2pFMoh0", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T19:56:00.000+03:00", "crawled": "2018-03-27T11:37:17.009+03:00", "highlightTitle": ""}